CRISPR Therapeutics
- تیر- 1397 -27 تیر
CRISPR Efficiency Tied to Cancer-Causing Process
CRISPR Efficiency Tied to Cancer-Causing Process CRISPR doesn’t work very well in human cells whose DNA-damage response is working normally. Instead, the genome-editing method selects…
-- بیشتر بخوانید -- - دی- 1396 -15 دیدیگر
CRISPR Therapeutics: Elucidating The New CRISPR/Cas9 Exploratory Findings
Summary Recent research published on BioRxIv questioned the CRISPR/Cas9 gene-editing platform based on its preliminary research that found preexisting antibodies to Cas9. Nevertheless, the tried-and-true…
-- بیشتر بخوانید -- - 15 دیدیگر
CRISPR Therapeutics: Assessing The Recent Capital Financing
Summary ۵M shares recently issued and expected to close on Jan. 08. The said capital financing is prudent and strategic to fund their potential breakthrough.…
-- بیشتر بخوانید -- - 15 دیدیگر
CRISPR Therapeutics – Corporate Update To Jump Start 2018
Summary Company is powering a robust portfolio of gene-editing and CAR-T to service the orphan diseases market. Dr. Novak recently transitioned to his new post…
-- بیشتر بخوانید -- - 15 دیدیگر
کریسپر درمانی:خرید ثانویه
CRISPR Therapeutics: Buy The Secondary Summary The stock has shown bullish price action recently. Wall Street’s reaction to the recent secondary offering appears favorable. A…
-- بیشتر بخوانید -- - آذر- 1396 -28 آذردیگر
CRISPR درمان: بررسی های اخیر سرمایه تامین مالی
CRISPR Therapeutics: Assessing The Recent Capital Financing Summary ۵M shares recently issued and expected to close on Jan. 08. The said capital financing is prudent…
-- بیشتر بخوانید -- - 28 آذردیگر
CRISPR Therapeutics – Corporate Update To Jump Start 2018
Summary Company is powering a robust portfolio of gene-editing and CAR-T to service the orphan diseases market. Dr. Novak recently transitioned to his new post…
-- بیشتر بخوانید -- - 17 آذر
CRISPR Therapeutics: Analysis Of And Update On The B-Thalassemia Franchise
Summary The company recently submitted a CTA for CTX-001 (the potential treatment for the blood disorder Beta-thalassemia). It’s the first application for the CRISPR/Cas9 gene-editing…
-- بیشتر بخوانید -- - 10 آذرکریسپر
?You Get A Dilution! You Get A Dilution! What About CRISPR Therapeutics
Summary EDIT and NTLA have now announced secondary equity offerings. Equity dilutions are very common among pre-clinical biotechs, these are no different. Is the remaining…
-- بیشتر بخوانید --
